The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 352:1720-1721 April 21, 2005 Number 16
NextNext

Pegaptanib and Age-Related Macular Degeneration

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Gragoudas, E. S.
-PubMed Citation
To the Editor: Gragoudas and coworkers (Dec. 30 issue)1 report that in a trial of pegaptanib in patients with exudative macular degeneration, patients treated with intravitreal injections of 0.3 mg of active substance had less functional deterioration than did the controls, who received sham injections. It is not clear why the highest concentration (3.0 mg) was less active. Furthermore, if the baseline ocular characteristics of the patients are carefully analyzed, there is a statistically significant difference between the lesions observed in the "best" group of patients, treated with the 0.3-mg dose, and the controls: both the size of choroidal neovascularization . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.